Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04268550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04268550 · ClinicalTrials.gov record · last posted 2026-03-23

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

StatusActive, Not Recruiting
PhasePhase 2
Started2020-04-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Amendment record 12 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 12 times since 2020-02-11; most recent amendment 2026-03-20. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-07-06
Status change Recruiting→Active, Not Recruitingv4
2020-04-03
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04268550
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Enrollment 124 participants
Start Date 2020-04-08
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-23